Welcome to the CCO Site

Thank you for your interest in CCO content. As a guest, please complete the following information fields. These data help ensure our continued delivery of impactful education. 

Become a member (or login)? Member benefits include accreditation certificates, downloadable slides, and decision support tools.

Submit

Personal Perspectives on HIV PrEP Use: My Decision, My Experience

In this podcast, I share my thoughts as a person who has chosen to take PrEP to protect myself from HIV infection. Listen in on my experience with daily oral PrEP use, how it has kept me healthy, and what opportunities future PrEP options may offer.
person default
Christian R. Pollard (Patient)
Released: January 3, 2022

Acknowledgements

Provided by Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by an educational grant from
Gilead Sciences, Inc.

Information on this Educational Activity

Faculty

Christian R. Pollard (Patient)
Patient

Program Medium

This program has been made available online.

Related Content

Dr Michelle Collins-Ogle and Clinical Care Options (CCO): HIV postexposure prophylaxis is recommended following a potential sexual exposure.

Michelle D. Collins-Ogle, MD, FAAP, FPIDS, AAHIVS Released: April 26, 2022

Clinical Care Options (CCO): expert commentary on major findings from EPIC-NSW and next steps in PrEP strategies and populationwide HIV prevention efforts

Prof. Don Smith Released: March 18, 2022

Slides from Dr Jason Schafer and Clinical Care Options (CCO): There are key management considerations for patients initiating LA cabotegravir for PrEP

person default Jason Schafer, PharmD, MPH Released: March 15, 2022

Audio from Dr Jason Schafer and Clinical Care Options (CCO): Data support the efficacy and safety of long-acting cabotegravir injections for PrEP

person default Jason Schafer, PharmD, MPH Released: March 14, 2022

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings